IMPORTANCE Chronic rhinosinusitis (CRS) can cause an obstruction of the tubal orifice and thereby compromise ventilation of the middle ear. The resulting negative pressure in the middle ear may, in turn, lead to the formation of an eardrum retraction pocket and subsequent acquired cholesteatoma. This study hypothesizes that CRS may increase the risk of cholesteatoma.
C hronic rhinosinusitis (CRS) is defined as a state of inflammation that persists in the paranasal sinuses for 12 weeks or more. 1 Chronic rhinosinusitis is among the most prevalent chronic disease entities affecting the adult population, 2 with an estimated annual prevalence of 4.9% to 16%. 3, 4 Inflammation of the sinonasal mucosa can cause obstruction of the sinus ostia as well as the opening of the eustachian tube, with subsequent impairment of middle ear pressure regulation. 5, 6 Sinusitis has been detected in 78% of patients with repetitive and intractable otitis media with effusion. 7 Evidence has shown that patients with CRS frequently develop middle ear disorders due to anatomic and functional connections. 5 Existing evidence suggests that improvements or the resolution of middle ear disorders often follow the successful treatment of sinusitis. 8, 9 Acquired cholesteatoma is a complex and relatively common disorder of the middle ear that was first recognized more than 3 centuries ago. 10, 11 Prevalence is highest among white patients, followed by black patients, with a reported annual incidence of 9.2 to 12.6 cases per 100 000 adults, affecting approximately 5 million people worldwide. 12 Acquired cholesteatoma is a histologically benign but behaviorally malignant lesion derived from an abnormal growth of keratinizing squamous epithelium in the temporal bone. 13 Cholesteatoma can cause widespread structural bony destruction in the middle ear cleft and at the base of the skull, 14 resulting in hearing loss and even mortality owing to the possibility of fatal intracranial complications. 10 Although the pathogenesis of acquired cholesteatoma remains controversial, 14, 15 the most compelling explanation is formation of a retraction pocket in the eardrum resulting from negative pressure in the middle ear that in turn is caused by dysfunction of the eustachian tube (hydrops ex vacuo theory). 14 The above evidence suggests that CRS can cause an obstruction of the tubal orifice and thereby compromise ventilation of the middle ear. 5, 7 The resulting negative pressure in the middle ear then leads to the formation of an eardrum retraction pocket and subsequent acquired cholesteatoma. It is reasonable to hypothesize that a prospective or comorbid association may exist between CRS and acquired cholesteatoma. However, to the best of our knowledge, no previous largescale study has investigated the risk of acquired cholesteatoma among patients with CRS; thus, this hypothesis remains epidemiologically unproven. The aim of this study was to determine whether patients with CRS face a higher risk of developing acquired cholesteatoma than do those without CRS. This large-scale epidemiologic study leveraged the statistical power of a nationwide, population-based cohort to elucidate these intricate relationships.
Methods

Database
A compulsory National Health Insurance (NHI) mechanism was implemented in Taiwan in 1995. The NHI manages the reimbursement of health care costs for 99% of the 23.5 million residents of Taiwan. All claims data are collected in the National Health Insurance Research Database (NHIRD) and managed by the Taiwan National Health Research Institute. 16 The NHIRD includes comprehensive medical data, including the records of registration, ambulatory and inpatient care, catastrophic illness, and a variety of data related to drug prescriptions. 17 Insurance reimbursement claims were acquired from the NHIRD, which makes them available for research purposes. This study was conducted in accordance with the Declaration of Helsinki. 18 It was also evaluated and approved by the Taipei Veterans General Hospital's institutional review board. Data were retrieved from the Longitudinal Health Insurance Database 2005 (http://nhird.nhri.org.tw/en/Data_Subsets .html#S3), a subset of the NHIRD. The database covers the period from 1996 to 2010, comprising original NHI medical claims associated with the ambulatory and inpatient care of 1 million enrollees. The National Health Research Institute is intended to eliminate all statistically significant differences in age or sex between randomly sampled groups and the beneficiaries of the NHI program. 16 The original identification numbers of beneficiaries were encrypted for privacy, using methods consistent with those applied to other data sets, to ensure that all claims data could be linked for the extraction of additional medically relevant data. Numerous researchers have used the Taiwan NHIRD in studies published in peer-reviewed journals.
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Study Population
The research design used in this study is outlined in Figure 1 . This research compiled data from a study cohort and a comparison cohort to investigate the association between CRS and the subsequent development of cholesteatoma. 
Key Points
Question Does chronic rhinosinusitis increase the risk of middle ear cholesteatoma?
Findings In this population-based study, 12 670 patients with chronic rhinosinusitis had a 69% increased risk of middle ear cholesteatoma within 8 years, compared with those without chronic rhinosinusitis.
Meaning A prospective association exists between chronic rhinosinusitis and middle ear cholesteatoma. Otologic examination of patients with chronic rhinosinusitis is essential to ensure the early detection and timely treatment of cholesteatoma.
The outcome variable was a diagnosis of cholesteatoma (ICD-9-CM codes 385.3 and 385. 30-385.33 ). Patients with a preexisting cholesteatoma or diagnosis of CRS were excluded from both cohorts. Potential confounders for the risk of cholesteatoma were identified as follows: allergic rhinitis (ICD-9-CM code 477.X), asthma (ICD-9-CM code 493.X), atopic dermatitis (ICD-9-CM codes 691.8, 692, and 692.9), cleft palate and/or lip (ICD-9-CM code 749.X), adenoid hypertrophy (ICD-9-CM code 474.X), history of ventilation tube insertion (Taiwan NHI payment code 84015B), and adenoid tonsillectomy (Taiwan NHI payment code 71008C). Inclusion criteria for cholesteatoma were similar to those for CRS, requiring that (1) patients had 2 or more ambulatory visits or 1 or more inpatient visit and (2) cholesteatoma diagnostic codes had been assigned by an otolaryngologist.
The towns and cities in Taiwan were stratified into 7 urbanization categories, in accordance with criteria established by the National Health Research Institute, with 1 indicating the highest level of urbanization and 7 indicating the lowest. Criteria included population density (persons per square kilometer), the percentage of people with a college-level education or higher, the percentage of people aged 65 years or older, the percentage of agricultural workers in the local population, and the number of physicians per 100 000 people. The number of allergic rhinitis cases in areas of levels 4, 5, 6, and 7 were low; therefore, these levels were combined into a single urbanization group referred to as level 4.
Statistical Analysis
We performed Pearson χ 2 tests to examine the differences in categorical data between cholesteatoma and the comparison cohorts, including the level of urbanization, monthly income, geographic region, and presence or absence of potential confounders. Parametric continuous data for the 2 cohorts, including follow-up times, were compared using a 2-tailed, unpaired t test. During the 8-year follow-up period, the Kaplan-Meier method was used to calculate cholesteatoma-free survival among all patients from the entry date to 1 of the following categories: censored dates of cholesteatoma occurrence, withdrawal from follow-up, loss to follow-up, death, or the end of the study period (December 31, 2010), whichever came first. We also applied the log-rank test to examine differences in the rates of cholesteatoma-free survival between cohorts. Cox proportional hazards regression analysis, stratified by sex, age group, index year, and relative confounders, was used to examine the risk of cholesteatoma in the CRS and comparison cohorts during the 8-year follow-up period. In both groups, we classified cases according to sex and age group. We also stratified the analysis of the follow-up period (3, 5, and 8 years) to assess the association between CRS and cholesteatoma events. Hazard ratios (HRs) and 95% CIs were calculated as a representation of the risk of cholesteatoma in each cohort. Effect sizes and 95% CIs around the absolute differences in rates are reported.
All data analysis was conducted using SAS System for Windows, version 9.3 (SAS Institute Inc) and SPSS, version 18.0 (IBM Corp). A P value <.05 was considered statistically significant. Data analysis was conducted from June 1 to October 27, 2015. Table 1 lists the distribution of demographic characteristics and comorbidities in the CRS and comparison cohorts. The CRS cohort contained 12 670 patients, and the comparison cohort contained 63 350 patients. A total of 35 220 (46.3%) of the population was female, and mean (SD) age was 27.57 (22.03) years. Between the CRS and non-CRS groups, we observed statistically significant differences in urbanization level, monthly income, and geographic region, as well as in the incidence rates of asthma, allergic rhinitis, atopic dermatitis, adenoid hypertrophy, and cleft palate and/or lip. Statistically significant differences were also observed in the rates of treatment with ventilation tube insertion or adenoid tonsillectomy between these 2 groups.
Results
Demographic Characteristics
Incidence Densities of Cholesteatoma
During the 8-year follow-up period, a total of 209 patients developed cholesteatoma, including 66 patients (101 084 person-years) in the CRS group and 143 patients (506 540 person-years) in the comparison group ( Table 2 ). The overall incidence density was more than 2-fold higher in the case cohort (0.65 per 1000 patientyears; 95% CI, 0.50-0.81 person-years) than in the comparison cohort (0.28; 95% CI, 0.24-0.33 per 1000 patient-years). The absolute difference in the incidence density between CRS and non-CRS groups was 0.37 (95% CI, 0.21-0.53) per 1000 patient-years. Patients with CRS had a higher incidence density than did the comparison individuals regardless of age, sex, and follow-up period. The higher age-specific incidence density of cholesteatoma was noted in both CRS and control adults (≥18 years) compared with children (0-17 years). The absolute difference in the incidence density between the CRS and non-CRS adult groups was 0.59 (95% CI, 0.31-0.87) per 1000 patient-years. The absolute difference in the incidence density between the CRS and non-CRS children groups was 0.08 (95% CI, 0.02-0.19) per 1000 patient-years. The incidence density stratified by sex revealed that female patients with CRS had a higher incidence density of cholesteatoma than did male patients with CRS (0.75; 95% CI, 0.50-1.00; vs 0.57; 95% CI, 0.37-0.77 per 1000 patient-years). Similar findings in the non-CRS group showed that females had a higher incidence density of cholesteatoma than did males (0.24; 95% CI, 0.18-0.30; vs 0.33; 95% CI, 0.12-0.54 per 1000 patientyears). The absolute difference in the incidence density between the CRS and non-CRS female groups was 0.42 (95% CI, 0.16-0.68) per 1000 patient-years. The absolute difference in the incidence density between the CRS and non-CRS male groups was 0.33 (95% CI, 0.12-0.54) per 1000 patient-years. The follow-up periodspecific incidence density tended to decrease with the 3 observation periods among CRS patients (0.97; 95% CI, 0. 
Risk of Cholesteatoma
Kaplan-Meier survival analysis ( Figure 2 ) revealed that patients with CRS presented a significantly lower 8-year cholesteatoma-free rate than did those in the comparison cohort. The absolute difference in the 8-year cholesteatoma-free survival rate between the CRS and non-CRS groups was 0.0029 (95% CI, 0.0016-0.0043). Cox regression analysis revealed that the crude HR of cholesteatoma was 2.31 times higher among patients with CRS (95% CI, 1.73-3.10) than among those in the comparison cohort (Table 2) . After adjusting for potential confounders, patients with CRS were 1.69 times (95% CI, 1.23-2.32) more likely to develop cholesteatoma than were those without CRS.
Time-Independent Hazard of Cholesteatoma
To determine whether CRS is a time-dependent risk factor for cholesteatoma, patients were divided into 3 subgroups according to the duration of follow-up: 3, 5, or 8 years (Table 2) . In all 3 follow-up periods, the risk of developing cholesteatoma remained significantly higher in the CRS group than in the comparison group, both before and after adjustment for potential confounders. The highest covariable-adjusted HR was noted in patients with CRS during the 3-year follow-up period (HR, 2.62; 95% CI, 1.65-4.17).
Age-Specific Hazard of Cholesteatoma
We also investigated whether CRS is an age-dependent risk factor for cholesteatoma by dividing patients into 2 subgroups according to age intervals (Table 2) . After adjusting for potential confounders, it was observed that adult patients (≥18 years) with CRS had a 61% increased risk of cholesteatoma within 8 years, compared with those without CRS (HR, 1.61; 95% CI, 1.16-2.24); however, no statistically significant differences between the CRS and control groups were observed in children (<18 years) (HR, 2.67; 95% CI, 0.75-9.48).
Sex-Specific Hazard of Cholesteatoma
Finally, we sought to determine whether CRS is a sexdependent risk factor for cholesteatoma (Table 2 ). Our re- Abbreviations: CRS, chronic rhinosinusitis; NT$, new Taiwan dollar. a Between the CRS and non-CRS groups, we observed statistically significant differences in urbanization level, monthly income, and geographic region, as well as in incidence rates of adenoid hypertrophy and cleft palate and/or cleft lip (all P < .001). Statistically significant differences were also observed in the rates of treatment with ventilation tube insertion or adenoid tonsillectomy between these 2 groups (all P < .001).
sults revealed that female patients with CRS faced a higher risk of developing cholesteatoma than did female individuals without CRS (HR, 1.55; 95% CI, 1.01-2.40). A statistically significant difference between the CRS and control groups was similarly observed among male patients (HR, 1.81; 95% CI, 1.14-2.89). Notably, female patients with CRS had a lower covariateadjusted HR than did male patients with CRS (adjusted HR, 1.55; 95% CI, 1.01-2.40; vs 1.81; 95% CI, 1.14-2.89).
Discussion
In this 8-year cohort study of 76 020 patients, we succeeded in identifying a prospective link between new diagnoses of CRS and the subsequent development of acquired cholesteatoma. Compared with those without CRS, the hazard risks for CRS participants of developing acquired cholesteatoma were increased 2.62-fold, 2.03-fold, and 1.69-fold within the 3-, 5-, and 8-year follow-up periods after adjusting for covariables. We also determined that CRS is an age-dependent (≥18 years) as well as non-sex-specific risk factor for cholesteatoma.
Potential Biological Mechanism Linking CRS to Cholesteatoma
Our results revealed what we believe to be previously unrecognized evidence linking CRS to subsequent cholesteatoma in the middle ear. Identification of such a prospective association may provide important insight into the epidemiology of both conditions and prompt further research into the possibility of an underlying pathophysiologic association. Although the underlying mechanisms linking the 2 disease entities are not clearly delineated, evidence suggests a plausible biological mechanism. A key factor in the linkage between CRS and cholesteatoma is the mechanical obstruction of eustachian tube orifices. In patients with CRS, inflammation may occur in the upper respiratory tract as well as in the adjacent eustachian tube. Inflammation and swelling of the mucosa in the eustachian tube can cause tubal stenosis or blockage. 23 Purulent sinonasal secretions transported over tubal orifices could lead to further tubal obstruction. A dysfunctional eustachian tube is unable to resupply gas to the middle ear, such that it remains in a state of constant negative pressure. Over time, the eardrum retracts and acquired middle ear cholesteatoma forms.
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Role of Common Biomolecular and Cellular Dysfunction in a United Airway
Research supports the notion that the middle ear may be part of a united airway in which a tight connection exists between the middle ear and the upper airway. 25 Emerging evidence suggests that similar biomolecular and cellular dysfunctions may be important intrinsic factors in CRS as well as middle ear cholesteatoma in this united airway. 26, 27 In addition, research has revealed that deficits in immunity (eg, overexpression of cytokines or chemokines) are apparent in patients with CRS 2,26,27 as well as in those with cholesteatoma. 14, 24 Furthermore, defective or overreactive Control group
CRS group
Significance at P < .001 was determined with a log-rank test. 
Clinical Implications
Our findings have meaningful diagnostic implications. The strong likelihood that CRS could be used as an indicator for the development of middle ear cholesteatoma underlines the importance of raising awareness among clinicians with regard to the possibility that the development of acquired cholesteatoma may be secondary to CRS. Thus, patients with CRS should be evaluated for cholesteatoma, and vice versa. Our findings may also have implications for research regarding possible and existing therapies. Studies have demonstrated the effectiveness of appropriate antibiotic treatment in patients with infectious diseases of the sinus and middle ear. 7 Successful treatment of sinus infections has also been shown to be associated with successful treatment of diseases in the middle ear. 8 In a similar fashion, timely and appropriate intervention for CRS control may have an indirect beneficial effect of preventing irreversible cholesteatomatous pathology in the middle ear cleft. Further research is warranted to establish a rational basis for surgical intervention as a preventive management strategy against acquired cholesteatoma, which might reduce the morbidity and health care costs associated with middle ear disease. 32 
Strengths and Limitations
The strength of this study lies in the application of the NHI nationwide data set. To our knowledge, no previous study has attempted to link CRS to middle ear cholesteatoma, which may be due in part to the low incidence of cholesteatoma, the small sample size typical of single institutions, and the high rate of individuals lost to follow-up. [33] [34] [35] This large-scale, populationbased survey helps to validate the newly discovered link by providing a large sample size with minimal selection bias and complete follow-up of cohort members. The mandatory health care system in Taiwan provides complete medical coverage to almost all residents (99%), and a very low copayment requirement ($3-$15 US) contributes to high utilization of medical services, thereby reducing the possibility of underestimating the number of cholesteatoma cases.
The findings of this study should be interpreted with caution. First, an epidemiologic association does not necessarily imply biological causation. Nonetheless, our discovery regarding a prospective link between CRS and cholesteatoma may serve as an early warning clue for potentially unrecognized cholesteatoma, thereby preventing a missed or delayed diagnosis of the disease. Second, we analyzed patients with newly diagnosed CRS to avoid the potential effects of chronicity. However, a new diagnosis does not necessarily imply that cholesteatoma was a recent development. A time lag prior to diagnosis may impede estimations related to the precise effect of disease duration on the development of comorbidity. In this study, participants in the CRS and non-CRS cohorts were followed up by their primary physicians and/or otolaryngologists for 8 years. However, the probability of diagnosing a cholesteatoma may be inherently higher in the CRS group than in the non-CRS group, if patients in the CRS group were monitored more diligently.
The incidence density of cholesteatoma among patients with CRS gradually decreased over time, from 0.97 to 0.65 per 1000 patient-years. In contrast, the incidence density of cholesteatoma among individuals without CRS remained relatively steady at 0.28 to 0.30 per 1000 patient-years throughout the follow-up period. These observations indicate that the effects of inflammation and/or infection are more severe during the period close to the onset of CRS. It therefore may be reasonable to expect a higher incidence density of cholesteatoma owing to compromised ventilation of the middle ear caused by inflammation and/or infection. In addition, the annual incidence of cholesteatoma ranges from approximately 9.0 to 12.6 cases per 100 000 adults and from 3.0 to 15.0 cases per 100 000 children. 24 Further studies will be required to determine the true difference in the incidence of cholesteatoma between children and adults in Taiwan; however, the higher incidence among adults may be an indication of bias in the inclusion criteria. Despite the fact that we included only patients who made 2 or more ambulatory visits or 1 or more inpatient visit, the chance of miscoding after a diagnosis may exist. In this study, there appeared to be a higher incidence of cholesteatoma among females; however, in the literature, the incidence of cholesteatoma is higher among males. 15 Further research may be required to clarify this point.
Finally, chronic eustachian tube dysfunction (type C tympanogram) may be associated with CRS leading to the formation of cholesteatoma. Audiograms and tympanograms may provide relevant information pertaining to the association between eustachian tube dysfunction and subsequent cholesteatoma. Such data are necessary for a comprehensive investigation of all potential risk factors included in analysis of covariables. However, the present study obtained secondary data from the NHIRD, which does not include data from the original medical records. Thus, comparative longitudinal prospective studies are also required to clarify these points.
Conclusions
Newly discovered epidemiologic evidence indicating a prospective link between CRS and middle ear cholesteatoma provides evidence to support building awareness among clinicians regarding the possibility that the development of cholesteatoma may be secondary to CRS. Close monitoring of middle ear status among patients with CRS may facilitate early detection and the timely treatment of comorbid cholesteatoma. Similarly, patients with cholesteatoma should be considered for evaluation of CRS.
